Hyderabad-based drugmaker Zenara Pharma has launched the first generic copy of Pfizer’s anti-covid pill -- nirmatrelvir and ritonavir combination tablet -- in India, under the brand name Paxzen.
The combination pack, as a treatment option for patients with symptoms of Covid-19, had undergone necessary trials in India following the generic licensing of the same by the US drug giant to Zanara and a few other local drug makers.
Paxzen, manufactured at Zenara’s US FDA and EU approved facility in Hyderabad, will be sold at a maximum retail price of Rs 5,200 per box, equivalent to one full course of treatment per patient.
Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, is the first company to launch the product in India.
(To receive our E-paper on whatsapp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)
